Oxford Biomedica PLC — Regulatory Filings 2015

Mar 5, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6274G

Oxford Biomedica PLC

05 March 2015

Oxford BioMedica Announces Presentation at 27th Annual ROTH Conference

Oxford, UK - 5 March 2015: Oxford BioMedica plc (LSE: OXB), ("OXB" or "the Company") a leading gene and cell therapy company, announces that Tim Watts, Chief Financial Officer, will present a company overview on 9 March 2015 at the 27th Annual ROTH Conference at the Ritz Carlton Laguna Niguel, CA, US. The OXB presentation will begin at / 2pm PST / 5pm EST / 10pm GMT.

A simultaneous webcast of the presentation will be accessible at http://wsw.com/webcast/roth29/oxb.l 

Following the presentation there will be an archived replay of the presentation available on the Company's website.

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer	Tel: +44 (0)1865 783 000
Media Enquiries: Mary-Jane Elliott/ Matthew Neal/ Chris Welsh/ Laura Thornton Consilium Strategic Communications	Tel: +44 (0)20 3709 5700

Notes to editors

About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy company with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Company's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp.  In addition, the Company has licenced products and IP to Sanofi, Pfizer, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk  and www.oxbsolutions.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUGUUUWUPAUBA